GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Elevation Oncology
Shares of Elevation Oncology, a biotech focused on precision oncology, reflect the progress of its clinical programs. The price trajectory depends on research results and investor confidence in its approach to cancer treatment.
Share prices of companies in the market segment - Cancer cure
Elevation Oncology is a biopharmaceutical company developing targeted therapies for the treatment of solid tumors with specific genomic mutations. We categorize the company as a "Cancer Treatment" company. The chart below shows how the market views personalized medicine approaches in oncology.
Broad Market Index - GURU.Markets
Elevation Oncology is an oncology company focused on developing targeted therapies for patients with rare genetic mutations in their tumors. Its approach to precision medicine makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Elevation compares to it.
Change in the price of a company, segment, and market as a whole per day
ELEV - Daily change in the company's share price Elevation Oncology
For Elevation Oncology, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Cancer cure
Elevation Oncology is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of cancers with specific genomic mutations. Oncology is a volatile sector. The chart below reflects the average fluctuations in this industry, providing context for evaluating ELEV stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Elevation Oncology is a biotech company developing drugs to treat cancer. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Elevation Oncology
Elevation Oncology's year-over-year performance is a story of its focus on precision medicine. Its market cap change over the past 12 months is entirely dependent on clinical trial data. The success of its drugs targeting rare genetic mutations could offer new hope for patients for whom other treatment options are lacking.
Annual dynamics of market capitalization of the market segment - Cancer cure
As an early-stage biotech, Elevation is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cancer drugs. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Elevation Oncology is a biotech whose value is locked into its pipeline of cancer drugs. Its shares move in sync with clinical trial news. A sharp rise or fall amid a calm market is clear evidence that investors are betting on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Elevation Oncology
Elevation is an oncology company. Its monthly performance is typical for early-stage biotech companies: it depends entirely on progress in its scientific developments and clinical programs. News of trial results are the main drivers of its value.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Elevation Oncology is a biotech company focused on precision medicine in oncology. It develops drugs for patients whose tumors have specific genetic mutations. The dynamics of the biotech sector reflect the hopes for personalized approaches. Elevation's history is in discovering and treating rare cancer subtypes where targeted therapy can be most effective.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Elevation Oncology, Inc. is a biopharmaceutical company focused on developing targeted therapies for the treatment of cancers with specific genomic mutations. The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how its scientific approach to precision oncology impacts its valuation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Elevation Oncology
Elevation Oncology is an oncology company focused on targeted therapies for genetically specific tumors. Its weekly stock price is volatile and depends on news about clinical trials and partnerships.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Elevation Oncology specializes in precision medicine, developing treatments for cancer patients with specific genomic mutations. This is the future of oncology. This chart will help you understand whether the company's stock price movement is driven by its own clinical data or a general reaction to news in the field of targeted therapy.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Elevation Oncology is a biotech company. Its shares move on news about clinical trials. This chart clearly demonstrates how much its performance is driven by scientific news rather than by general market trends, which create their own path.
Market capitalization of the company, segment and market as a whole
ELEV - Market capitalization of the company Elevation Oncology
Elevation Oncology's market capitalization reflects its focus on precision medicine, specifically developing drugs for patients with rare genomic mutations in their tumors. Its volatile price chart reflects how investors view its ability to find and treat these small patient populations, a challenging but potentially lucrative strategy.
ELEV - Share of the company's market capitalization Elevation Oncology within the market segment - Cancer cure
Elevation Oncology is a company focused on targeted cancer therapy. Its market share in the vast oncology sector is small, typical for clinical-stage biotech. Its market capitalization is a barometer of its research progress and the market's confidence in the success of its approach to treating rare genetic mutations.
Market capitalization of the market segment - Cancer cure
Here's a chart showing the biotech sector's market capitalization. Elevation Oncology is a precision oncology company. Its strategy is to identify rare genetic mutations that drive cancer and develop targeted drugs against them. Its market history exemplifies how focusing on rare targets can create significant value.
Market capitalization of all companies included in a broad market index - GURU.Markets
Elevation Oncology is an oncology company developing targeted drugs for the treatment of cancers caused by specific genetic mutations. Its market capitalization reflects its focus on precision medicine. The chart below shows the economic weight of companies in this field.
Book value capitalization of the company, segment and market as a whole
ELEV - Book value capitalization of the company Elevation Oncology
Elevation Oncology's foundation is its capital and strategy for developing targeted therapies for cancers with rare genomic mutations. This chart tells the story of a biotech company that, after failing with its first drug, uses its capital to identify and acquire new, more promising assets.
ELEV - Share of the company's book capitalization Elevation Oncology within the market segment - Cancer cure
Elevation Oncology develops targeted therapies for tumors with rare mutations. The chart shows its share of actual R&D assets. These include its laboratories and clinical programs, which form the foundation for its precision medicine approach.
Market segment balance sheet capitalization - Cancer cure
Elevation Oncology is a biotech company focused on targeted cancer therapy. Their asset-light model emphasizes clinical trials rather than plant construction. A book-to-market chart shows their modest financial base, as their primary asset is science.
Book value of all companies included in the broad market index - GURU.Markets
Elevation Oncology's assets include laboratories and R&D centers for developing targeted therapies targeting rare genetic mutations in tumors. The chart shows how the company built its scientific and material foundation.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Elevation Oncology
Elevation Oncology is a company focused on targeted cancer therapy. Its book value is primarily derived from cash flow from research. The chart below is a barometer of faith in its scientific approach. Its market capitalization is a bet on its drug candidates successfully completing trials and reaching the market.
Market to book capitalization ratio in a market segment - Cancer cure
Elevation Oncology is a biotech company focused on precision medicine, developing targeted therapies for cancers with specific rare genetic mutations. Its valuation is based on the potential of this targeted approach. The chart reflects how the market views the prospects of its clinical developments.
Market to book capitalization ratio for the market as a whole
Elevation Oncology is a company focused on precision oncology. Its value lies in its pipeline of developments targeting genetic mutations. This chart shows that its market capitalization reflects investor confidence in the success of its scientific approach, rather than the valuation of its tangible assets, which is typical for innovative biotech companies.
Debts of the company, segment and market as a whole
ELEV - Company debts Elevation Oncology
Elevation Oncology is a biotech company focused on precision medicine for cancer treatment. This chart illustrates its strategy. The company identifies rare genomic mutations and develops targeted drugs for these small patient populations, which requires significant investment in diagnostics and clinical trials.
Market segment debts - Cancer cure
Elevation Oncology is a biotech company focused on precision medicine, developing drugs for patients with specific genetic mutations in their tumors. This approach requires sophisticated diagnostic tools and targeted research. This chart reflects the company's financial strategy in this cutting-edge field of oncology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Elevation Oncology
Elevation Oncology is a biopharmaceutical company focused on targeted cancer therapy. This chart shows its financial structure. As with most development-stage biotechs, debt is a huge risk. Financing must be equity-based to avoid creditor pressure.
Market segment debt to market segment book capitalization - Cancer cure
Elevation Oncology is a biopharmaceutical company focused on developing targeted therapies for cancers with specific genomic mutations. This chart shows the debt burden in the biotech sector, indicating the company's ability to fund its high-precision and expensive research.
Debt to book value of all companies in the market
Elevation Oncology is a biotech company focused on targeted therapies for cancers with specific genetic mutations. This is at the forefront of personalized medicine. This graph of total debt in the market serves as an indicator of investor risk appetite, which directly impacts the company's ability to fund its highly specialized research.
P/E of the company, segment and market as a whole
P/E - Elevation Oncology
Elevation Oncology is a biotech company focused on developing targeted therapies for cancers caused by specific genomic mutations. This chart reflects investors' faith in the personalized oncology paradigm. Its performance is entirely dependent on the success of clinical trials for its drugs in specific patient groups.
P/E of the market segment - Cancer cure
Elevation Oncology is a biotech company focused on developing targeted therapies for cancer patients with rare genomic mutations. It's an example of precision medicine. This chart shows the average valuation for the oncology sector, reflecting how investors value personalized approaches to cancer treatment.
P/E of the market as a whole
Elevation Oncology is a biotech company specializing in the development of targeted therapies for cancer treatment. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Elevation Oncology
Elevation Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of cancer patients with rare genomic mutations. This graph reflects market expectations for the success of its precision approach to oncology. Future revenue is dependent on clinical trial results and commercialization.
%20P%2FE%20Elevation%20Oncology&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Elevation-Oncology&v=1772643206843 "Chart of the company's future (projected) P/E Elevation Oncology")
Future (projected) P/E of the market segment - Cancer cure
Elevation Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of cancers caused by specific genomic alterations. The chart reflects average expectations for the oncology segment. ELEV's position relative to this benchmark reflects investor assessment of its precision medicine approach and the potential of its drugs for niche patient groups.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772643206879 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Elevation Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of solid tumors with specific genomic mutations. This approach is a "precision medicine" approach to oncology. This chart of overall market expectations shows how willing investors are to fund highly specialized oncology developments with a clearly defined patient population.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772643206907 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Elevation Oncology
Elevation Oncology is a biotech company focused on developing targeted therapies for the treatment of cancer patients with specific genomic mutations. Its financial performance reflects significant investments in clinical trials. Future profitability depends on the success of its precision medicine approach to oncology.
Profit of companies in the market segment - Cancer cure
Elevation Oncology is a biopharmaceutical company focused on developing targeted drugs to treat cancer patients with specific genomic mutations. This approach is precision medicine. This chart reflects the overall revenue in the cancer treatment sector. It demonstrates the industry's success in developing and commercializing highly targeted but potentially highly effective drugs.
Overall market profit
Elevation Oncology is a biopharmaceutical company focused on developing targeted therapies for cancers caused by specific genomic mutations. Its future depends on the success of its clinical programs. The positive economic backdrop, visible in this chart, is critical for attracting investment, as targeted oncology requires significant R&D expenditures.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Elevation Oncology
Elevation Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of cancers caused by specific genetic mutations. This graph reflects analyst expectations for the commercial potential of its precision medicine approach, which depends on the success of clinical trials and the identification of target patient groups.
%20profit%20of%20the%20company%20Elevation%20Oncology&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Elevation-Oncology&v=1772643207104 "Graph of future (projected) profit of the company Elevation Oncology")
Future (predicted) profit of companies in the market segment - Cancer cure
Elevation Oncology is a biotech company focused on developing targeted therapies for the treatment of cancer patients with rare genomic mutations. This approach enables the creation of highly effective drugs for small patient populations. This chart reflects forecasts for the biotech sector, providing context for assessing Elevation's potential in precision oncology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772643207111 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Elevation Oncology is a biotechnology company focused on precision medicine for cancer treatment. Its value and future are determined solely by the results of clinical trials and the potential of its scientific developments. The overall macroeconomic indicators presented in this chart are irrelevant to the company.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772643207127 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Elevation Oncology
Elevation Oncology is a biotech company focused on precision medicine for treating cancer patients with rare genetic mutations. This chart demonstrates the high valuation of its niche yet scientifically sound approach. This trend reflects progress in clinical trials and confidence in the future of personalized oncology.
P/S market segment - Cancer cure
Elevation Oncology is a biotech company focused on developing targeted therapies for cancers defined by specific genetic mutations. Future revenue depends on the success of its drugs. This chart for the oncology sector compares investor expectations for Elevation Oncology's precise approach with those of other companies.
P/S of the market as a whole
Elevation Oncology is a biotech company specializing in the development of targeted therapies for the treatment of cancer patients with rare genomic mutations. This approach enables the creation of highly effective drugs for small but clearly defined patient groups. This market revenue valuation chart helps understand how investors view this precision oncology strategy.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Elevation Oncology
Elevation Oncology is an oncology company focused on developing targeted therapies for cancer patients with specific genomic mutations. This chart shows how the market perceives the future commercial potential of its developments. It reflects its belief in personalized medicine and the success of its clinical programs.
%20P%2FS%20Elevation%20Oncology&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Elevation-Oncology&v=1772643207216 "The graph of the company's future (projected) P/S Elevation Oncology")
Future (projected) P/S of the market segment - Cancer cure
Elevation Oncology is a biotech company specializing in precision medicine. It develops targeted drugs for the treatment of cancer patients whose tumors harbor specific genomic mutations. The company's valuation is based on investors' confidence in its strategy for developing drugs for clearly defined patient groups, which could accelerate the approval process.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772643207247 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Elevation Oncology is a biotech company focused on developing targeted therapies for cancers caused by specific genetic mutations. It is an example of personalized medicine. In the context of the overall revenue projections shown in the chart, the company represents the future of oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772643207249 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Elevation Oncology
Elevation Oncology is a biotechnology company focused on developing targeted therapies for the treatment of cancer patients with specific genomic mutations. Being in the clinical stage, the company has no commercial revenue from product sales. Any revenue in the chart may be related to partnerships.
Sales of companies in the market segment - Cancer cure
Elevation Oncology (ELEV) is an oncology company focused on developing targeted therapies for patients with cancers harboring specific genomic mutations. This chart shows revenue in the oncology sector. Elevation Oncology's precision medicine approach enables the development of effective treatments for specific patient groups unresponsive to standard treatments.
Overall market sales
Elevation Oncology is a biotech company focused on developing targeted therapies for genetically specific cancers. Its development depends on scientific advances and funding. This graph, reflecting the state of financial markets, affects the availability of capital for niche oncology companies. Market growth facilitates fundraising for clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Elevation Oncology
Elevation Oncology is a biotech company focused on developing targeted therapies for the treatment of cancer patients with rare genetic mutations. Its future revenue depends on the success of clinical trials and the commercialization of its targeted therapies. This chart reflects analyst forecasts, which assess the potential of its precision approach in oncology.
%20sales%20of%20the%20company%20Elevation%20Oncology&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Elevation-Oncology&v=1772643207430 "Schedule of future (projected) sales of the company Elevation Oncology")
Future (projected) sales of companies in the market segment - Cancer cure
Elevation Oncology is a biopharmaceutical company specializing in the development of targeted therapies for the treatment of cancer patients with rare genomic mutations. This graph shows the potential future revenue from their pipeline of candidates. This is an analyst's perspective on the commercial prospects of their precision approach to oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772643207455 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Elevation Oncology is a biotech company focused on precision medicine. It identifies patients with rare genetic mutations in their tumors and develops drugs specifically for them. This chart illustrates the general investment climate, but Elevation's model is based on a deep understanding of cancer genomics, which is the future of personalized oncology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772643207498 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Elevation Oncology
Elevation Oncology is a biopharmaceutical company specializing in the development of targeted therapies for cancers caused by specific genetic mutations. While in clinical trials, it incurs significant expenses. The chart shows the financial health of the company, whose future profitability depends on the success of this precise, targeted treatment approach.
Market segment marginality - Cancer cure
Elevation Oncology is a biopharmaceutical company focused on developing targeted therapies for the treatment of cancers caused by specific genomic mutations. This chart reflects its operating expenses. Like other biotech companies, the path to profitability lies through successful clinical trials and regulatory approval.
Market marginality as a whole
Elevation Oncology is a biotech company focused on precision medicine for the treatment of cancer caused by rare genetic mutations. This total return chart reflects investor appetite for highly specialized and risky projects. Economic growth and market optimism facilitate capital raising for such niche developments.
Employees in the company, segment and market as a whole
Number of employees in the company Elevation Oncology
Elevation Oncology is a precision medicine company developing targeted drugs to treat cancer patients whose tumors harbor rare genetic mutations. This graphic shows a focused team identifying and developing drugs for small but clearly defined groups of cancer patients.
Share of the company's employees Elevation Oncology within the market segment - Cancer cure
Elevation Oncology is a biotech company focused on precision medicine for cancer treatment. Its approach involves identifying patients with specific genomic mutations. This chart shows the company's team of scientists and clinicians dedicated to developing targeted therapies, reflecting its commitment to personalized approaches in oncology.
Number of employees in the market segment - Cancer cure
Elevation Oncology focuses on developing targeted therapies for cancers caused by specific genomic mutations. This chart, which reflects employment in the cancer treatment sector, highlights the shift toward personalized medicine. For Elevation, the growing number of geneticists and oncologists indicates increased demand for their approach, which targets rare but well-defined patient groups.
Number of employees in the market as a whole
Elevation Oncology is a biotech company focused on developing targeted therapies for cancer patients with specific genetic mutations. This is at the forefront of personalized medicine. The growth in overall employment, reflected in this chart, indicates a healthy economy capable of supporting expensive research and the implementation of cutting-edge treatments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Elevation Oncology (ELEV)
Elevation Oncology (ELEV) is a precision oncology company (genomics-based cancer treatment). In this business, market capitalization is a bet on the success of their clinical trials. This chart shows that value is created not by the number of employees, but by the quality of their R&D and the potential of their targeted drugs. This is a measure of intellectual capital.
%20of%20the%20company%20Elevation%20Oncology%20(ELEV)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Elevation-Oncology-ELEV&v=1772643207612 "Chart of market capitalization per employee (in thousands of dollars) of the company Elevation Oncology (ELEV)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Elevation Oncology is a biopharmaceutical company focused on precision oncology. Its approach is to identify specific mutations and develop drugs that target them. This chart shows how the market views this focused and potentially highly effective business model, based on deep scientific expertise.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772643207634 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Elevation Oncology is a biotech company focused on precision medicine—developing drugs for patients with specific genetic mutations in tumors. This chart for Elevation demonstrates how, in modern oncology, the cost per employee can be very high, as targeted drugs can be extremely effective for their target groups.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772643207654 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Elevation Oncology (ELEV)
Elevation Oncology is a clinical-stage biotech company developing targeted cancer therapies. The company is not profitable. This graph will reflect a negative value—the amount of investment (loss) per employee. This shows how much the company spends on research and clinical trials.
%20Chart%20Elevation%20Oncology%20(ELEV)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Elevation-Oncology-ELEV&v=1772643207670 "Company Profit Per Employee (in thousands of dollars) Chart Elevation Oncology (ELEV)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Elevation Oncology focuses on developing targeted therapies for cancer patients with rare genetic mutations. In precision oncology, success depends on a small but highly skilled team of scientists and clinicians. This graph reflects the value created by each employee, which is critical for biotech companies focused on personalized medicine.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772643207676 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Elevation Oncology is a biotech company that discovers and develops targeted drugs for the treatment of cancers caused by specific genetic mutations (fusion drivers). This chart, showing the market average earnings per employee, provides important context. It illustrates the high stakes in biotech, where a single successful development can generate colossal profits per scientist.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772643207677 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Elevation Oncology (ELEV)
Elevation Oncology is a biotech company focused on precision medicine for the treatment of cancer patients with rare genomic mutations. Being in clinical development, it has no commercial revenue yet. This graph will show zero values, which is typical for R&D companies whose value is determined by the potential of their scientific discoveries.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Elevation-Oncology-ELEV&v=1772643207693 "Sales chart per company employee Elevation Oncology (ELEV)")
Sales per employee in the market segment - Cancer cure
Elevation Oncology (ELEV) is a biotech company focused on developing targeted therapies for the treatment of cancers caused by specific genetic mutations. This chart shows the average revenue per employee in the sector. It is important for assessing R&D efficiency and personnel structure compared to other oncology biotechs.
Sales per employee for the market as a whole
Elevation Oncology (ELEV) is a biotech company working in the field of precision oncology. They search for specific genetic mutations in tumors and develop targeted drugs against them. The company has no commercial revenue. This near-zero figure reflects investments in its team of scientists and genomicists searching for new targets for cancer treatment.
Short shares by company, segment and market as a whole
Shares shorted by company Elevation Oncology (ELEV)
Elevation Oncology (ELEV) is a clinical-stage biotech focused on precision medicine (targeted therapy) for cancer treatment. This chart shows short interest. As with many early-stage biotechs, the high bearish bets reflect the enormous risk that their scientific hypotheses will not be confirmed in expensive clinical trials. (347)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Elevation-Oncology-ELEV&v=1772643207732 "Short Shares Chart for the Company Elevation Oncology (ELEV)")
Shares shorted by market segment - Cancer cure
Elevation Oncology (ELEV) focuses on developing targeted therapies for cancers caused by specific genomic mutations. The chart below shows the overall short position in the oncology biotech sector. It reflects how skeptical investors are overall about the success of highly specialized clinical trials.
Shares shorted by the overall market
Elevation Oncology is a biotech focused on targeted cancer therapy. This chart illustrates the overall market "fear." When investors panic, they're unwilling to fund "long-term science." They see their cash being burned and sell off their shares, fearing the company won't survive to commercial success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Elevation Oncology (ELEV)
Elevation Oncology (ELEV) focuses on "precision oncology"—discovering and developing drugs for patients with rare genetic mutations in tumors. It's a niche biotech. This chart measures the rate of price change. It shows when the stock is "overheated" (above 70) pending data or "oversold" (below 30) due to delays or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Elevation-Oncology-ELEV&v=1772643207767 "RSI 14 indicator chart for the company's stock Elevation Oncology (ELEV)")
RSI 14 Market Segment - Cancer cure
Elevation Oncology is an oncology company specializing in precision medicine. They develop targeted drugs to treat cancers caused by rare genetic mutations (fusions). This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire speculative segment is overheated.
RSI 14 for the overall market
For Elevation Oncology, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ELEV (Elevation Oncology)
Elevation Oncology is a biopharmaceutical company focused on precision oncology. It develops targeted therapies that target specific genetic mutations that cause cancer. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ELEV-Elevation-Oncology&v=1772643207788 "A chart showing analyst consensus forecasts for the expected stock price. ELEV (Elevation Oncology)")
The difference between the consensus estimate and the actual stock price ELEV (Elevation Oncology)
Elevation is a precision oncology company. The biotech company develops targeted drugs to treat cancers with rare genetic mutations. This chart shows how far the current share price differs from its "fair" value. It reflects analysts' confidence in their R&D portfolio and the success of this "sniper" approach to treatment.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ELEV-Elevation-Oncology&v=1772643207834 "A chart showing the difference between the consensus forecast and the actual stock price. ELEV (Elevation Oncology)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Elevation Oncology is a biotech company using a precision approach. It searches for rare genetic mutations in tumors and develops drugs that precisely target them. This chart shows the general expectations of analysts in the oncology sector. It reflects whether experts believe in the future of hyper-targeted therapy.
Analysts' consensus forecast for the overall market share price
Elevation Oncology is a biotech company specializing in precision oncology: they identify rare genetic mutations and develop targeted drugs for them. This chart reflects the overall market "risk appetite." For Elevation, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Elevation Oncology
Elevation Oncology is a biotech R&D company focused on precision oncology. Their focus isn't on broad cancer types, but on targeted therapies for patients with rare genetic mutations (fusions). This chart is a pure indicator of their faith in R&D. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) pipeline and their clinical trial data.
AKIMA Market Segment Index - Cancer cure
Elevation Oncology is a biotech company that works on the principle of one mutation, one drug. They search for rare genetic drivers of cancer and develop targeted therapies to combat them. This chart compares their composite index to the sector, showing how their sniper approach to cancer treatment is ahead of the curve.
The AKIM Index for the overall market
Elevation Oncology is an oncology company developing targeted therapies (antibody conjugates) for patients with specific genomic alterations. This chart, which reflects the market average, provides a macro backdrop. It helps assess how ELEV, focused on precision medicine, compares to overall economic trends.
